Victoria Socha

DocwireNews

Recipients of solid organ transplants commonly experience hyperkalemia, limiting use of pharmacotherapy in those patients. <a href="https://www.docwirenews.com/docwire-pick/nephrology-picks/szc-potassium-hyperkalemic-dialysis/">Hyperkalemia</a> is associated with multifactorial causes, including kidney dysfunction, calcineurin inhibitor use, and infection prophylaxis. The effect of sodium zirconium cyclosilicate (SZ-9) on potassium in the general population has been studied; however, the impact of SZ-9 on immunosuppression in transplant recipients is unknown.At the 2020 virtual American Transplant Congress, R. Winstead and colleagues reported results from a study designed to examine the effect of SZ-9 on potassium and tacrolimus levels in kidney, liver, and heart transplant recipients with hyperkalemia. The results were reported in a poster titled <a href="https://atcmeetingabstracts.com/abstract/sodium-zirconium-cyclosilicate-use-in-solid-organ-transplant-recipients-and-its-effect-on-potassium-and-immunosuppression/">Sodium Zirconium Cyclosilicate Use in Solid Organ Transplant Recipients and its Effect on Potassium and Immunosuppression</a><a href="https://atcmeetingabstracts.com/abstract/sodium-zirconium-cyclosilicate-use-in-solid-organ-transplant-recipients-and-its-effect-on-potassium-and-immunosuppression/">.</a>The researchers conducted a single center, retrospective medical record review of adult kidney, lover, and heart transplant recipients prior to and following initiation of ZS-9. Excluded patients initiated SZ-9 within 7 days of transplant or received the drug for fewer than 7 days. Patient evaluations were conducted at the time of diagnosis of hyperkalemia and 7 days after diagnosis.Patients were expected to take SZ-9 two hours apart from other medications; dosing frequency ranged from once daily to three times daily. The primary outcome of interest was change in potassium from day 0 to day 7. Secondary outcomes were change in tacrolimus, sodium, and bicarbonate levels form day 0 to day 7, and any reported adverse effects. Characteristics and outcomes were assessed with both parametric and nonparametric statistical tests.The analysis included records of 35 patients: 16 kidney transplant recipients, 14 liver transplant recipients, two heart transplant recipients, two combined kidney and liver transplant recipients, and one combined kidney and heart transplant recipient. Median time from transplant was 75 days.Overall, nine patients initiated SZ-9 as an inpatient and 12 received three times a day dosing for severe hyperkalemia (mean potassium level, 6.2 mEq/L). The mean decrease in potassium from day 0 to day 7 was &ndash;1.3 mEq/L (P&lt;.001) with a mean day 0 level of 5.9 mEq/L. Mean change in tacrolimus concentration was &ndash;0.54 ng/mL (P=.82). Mean change in sodium and bicarbonate concentrations from day 0 to day 7 were +1.70 mEq/L (P=.002) and +1.60 mEq/L (P=.006), respectively.The most common reasons for discontinuation of SZ-9 were resolution of hyperkalemia due to improvement in renal function and/or discontinuation of sulfamethoxazole/trimethoprim. There were two reports of mild edema.In conclusion, the researchers said, &ldquo;SZ-9 successfully lowered the potassium level from day 0 to day 7 in transplant recipients on calcineurin inhibitors with no apparent significant impact on tacrolimus drug pharmacokinetics. Further studies are needed to study whether SZ-9 impacts other commonly used transplant medications such as mycophenolate.&rdquo;Source: Winstead R, Demehin M, Yakubu I, et al. Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression. Abstract of a poster presented at the virtual American Transplant Congress (Abstract D-220), May 30, 2020.

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

Hyperkalemia in Solid Organ Transplant Recipients

American Transplant Congress 2020

Recipients of solid organ transplants commonly experience hyperkalemia, limiting use of pharmacotherapy in those patients. Hyperkalemia is associated with multifactorial ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe